FDA expands approval of Merck's Keytruda to lung cancer

(Reuters) - The U.S. Food and Drug Administration on Friday approved Merck & Co Inc's immunotherapy, Keytruda, for patients with the most common form of lung cancer whose tumors produce a specific biological marker.